FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia
Go back to Newsroom
FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia
The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature
Go back to Resources
The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature
Authors:
Volume:
Pagination:
Issue:
Journal:
PMID:
Keywords:
Abstract:
Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease
Go back to Resources
Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease
Authors:
Volume:
Issue:
Journal:
PMID:
Keywords:
Abstract:
Emmes Appoints Matt Bond as CFO
Go back to Newsroom
Emmes Appoints Matt Bond as CFO
Emmes Appoints Matt Bond as CFO
Reportedly, Matt Bond’s expertise in mergers and acquisitions (M&A) and his track record with successful private-equity-backed enterprises are expected to be valuable assets in Emmes’ growth and diversification strategy.
US-based Clinical Research Organisation (CRO) Emmes has named Matt Bond as its Chief Financial Officer (CFO), succeeding former CFO Brian Hochheimer.
Go back to Newsroom
Reportedly, Matt Bond’s expertise in mergers and acquisitions (M&A) and his track record with successful private-equity-backed enterprises are expected to be valuable assets in Emmes’ growth and diversification strategy.
US-based Clinical Research Organisation (CRO) Emmes has named Matt Bond as its Chief Financial Officer (CFO), succeeding former CFO Brian Hochheimer.
US-Based Emmes Acquires VaxTRIALS
Go back to Newsroom
US-Based Emmes Acquires VaxTRIALS
US-Based Emmes Acquires VaxTRIALS
This strategic acquisition is part of Emmes’ broader objective to expand its global presence beyond its existing operations in North America, Europe, and Asia into the Latin American market. The move is expected to strengthen Emmes’ expertise in one of its core research focus areas: vaccines and infectious diseases.
US-based Clinical Research Organisation (CRO) Emmes has acquired VaxTRIALS, a specialised Clinical Research Organisation headquartered in Panama City.
Go back to Newsroom
This strategic acquisition is part of Emmes’ broader objective to expand its global presence beyond its existing operations in North America, Europe, and Asia into the Latin American market. The move is expected to strengthen Emmes’ expertise in one of its core research focus areas: vaccines and infectious diseases.
US-based Clinical Research Organisation (CRO) Emmes has acquired VaxTRIALS, a specialised Clinical Research Organisation headquartered in Panama City.
Emmes announces reorganization and launch of AI unit
Go back to Newsroom
Emmes announces reorganization and launch of AI unit
Emmes announces reorganization and launch of AI unit
Go back to Newsroom
Psychedelic Therapy Faces Regulatory Hurdles Despite Promising Research
Go back to Newsroom
Psychedelic Therapy Faces Regulatory Hurdles Despite Promising Research
Psychedelic Therapy Faces Regulatory Hurdles Despite Promising Research
Key Insights
Go back to Newsroom
Key Insights
A CRO Should be the Partner that Gives Full Visibility on a Gene Therapy Trials Path
Go back to Newsroom
A CRO Should be the Partner that Gives Full Visibility on a Gene Therapy Trials Path
A CRO Should be the Partner that Gives Full Visibility on a Gene Therapy Trials Path
Go back to Newsroom
Essex Management Appoints David Loose as Chief Executive Officer Appointment Reflects Commitment to Continuing Essex’s Strategic Vision ROCKVILLE, MD
Go back to Newsroom
Essex Management Appoints David Loose as Chief Executive Officer Appointment Reflects Commitment to Continuing Essex’s Strategic Vision ROCKVILLE, MD
Essex Management Appoints David Loose as Chief Executive Officer Appointment Reflects Commitment to Continuing Essex’s Strategic Vision ROCKVILLE, MD
Essex Management, an Emmes Group company and a leader in biomedical informatics and health information technology, is pleased to announce the appointment of David Loose as Chief Executive Officer (CEO), effective immediately. David succeeds Kevin Hurley, who has served as CEO since February 2019 and will transition to the role of Executive Advisor.
Download Go back to Newsroom
Essex Management, an Emmes Group company and a leader in biomedical informatics and health information technology, is pleased to announce the appointment of David Loose as Chief Executive Officer (CEO), effective immediately. David succeeds Kevin Hurley, who has served as CEO since February 2019 and will transition to the role of Executive Advisor.
SCOPE Summit 2025: Emmes' Peter Ronco on Small Biopharma & Clinical Trial Partnerships
Go back to Newsroom
SCOPE Summit 2025: Emmes' Peter Ronco on Small Biopharma & Clinical Trial Partnerships